Search results

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

ANSTO’s Innovation Precinct welcomes NSW Government’s $12.5 commitment funding.

Bushfires in proximity to ANSTO during the 2018 bushfires.

Australia’s new state-of-the-art nuclear medicine facility gets green light.

See details of previously published customer updates from our Health products team. 

ANSTO to receive a new grant to continue to fight chronic kidney disease killer in Sri Lanka.

ANSTO offers a broad range of programs and services to various industries and customers. Many of these services, including the Australian Nuclear Medicine Traceability program, are supported by online customer portals.

This afternoon, the Chair of ANSTO, Dr Annabelle Bennett, wrote to all staff to let them know that CEO Dr Adi Paterson has decided to resign. She said the Board is deeply appreciative of the contributions Adi has made, including to the health, research and academic outputs of ANSTO during his tenure. Mr Shaun Jenkinson will continue as Acting CEO, while the Board undertakes a global search for a permanent CEO.

ANSTO's OPAL reactor is one of the world's most advanced and reliable research reactors today. To ensure we can continue operating OPAL safely and reliably and maximise utilisation, ANSTO must regularly carry out maintenance and upgrades.